[Pharmacologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results].
The Authors propose a medical treatment for Benign Prostatic Hyperplasia (BPH) using mepartricina-simvastatina, two drugs with a hypocholesterolemizing action. We have treated fifty patients with BPH (twelve with permanent catheters) obtaining a complete clinical results in 40% of the total and a partial clinical result in 38%. This therapy, in association with a correct diet and adequate physical activity, significantly improved not only the cervicurethral obstruction but also general hematochemical and, above all, lipidemic parameters.
Marino
G
G
Divisione di Urologia, Ospedale Mauriziano Umberto I, Torino.
Pugno
E
E
Cevoli
R
R
Griffa
D
D
Pastorini
S
S
Cocimano
V
V
D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008613:Mepartricin / Q000627:therapeutic use*; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D019821:Simvastatin
D000924:Anticholesteremic Agents; D008613:Mepartricin; D008148:Lovastatin; D019821:Simvastatin
Un razionale farmacologico per l'ipertrofia prostatica benigna (IPB): associazione di mepartricina e simvastatina. Analisi e risultati.